Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds
Details for Australian Patent Application No. 2009244199 (hide)
International Classifications
Event Publications
4 August 2011 Section 223 Application Received
Sinha, Santosh C.; Beard, Richard L.; Chow, Ken; Garst, Michael E.; Allergan, Inc.; Donello, John E.; Bhat, Smita An application to extend the time from 08 Dec 2010 to 08 Jun 2011 in which to enter the National Phase has been filed . Address for service in Australia - Davies Collison Cave Level 14 255 Elizabeth Street Sydney NSW 2000
22 September 2011 Section 223 Application Allowed
Sinha, Santosh C.; Beard, Richard L.; Chow, Ken; Garst, Michael E.; Allergan, Inc.; Donello, John E.; Bhat, Smita The time in which to enter the National Phase has been extended to 08 Jun 2011. Address for service in Australia - Davies Collison Cave Level 14 255 Elizabeth Street Sydney NSW 2000
6 October 2011 PCT application entered the National Phase
PCT publication WO2009/137681 Priority application(s): WO2009/137681
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2009244200-Medical failure pattern search engine
2009244197-3-hydroxy gepirone for the treatment of attention deficit disorder and sexual dysfunction
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser